New study reveals why some breast cancers resist advanced hormone therapy

A new study has uncovered why some advanced breast cancer patients develop resistance to next-generation estrogen receptor alpha (ERα) antagonists. Published in Nature Communications, the research highlights a shift in cancer cell identity as a key factor. Unlike earlier theories, this work points to changes in cellular lineage rather than just genetic mutations.

Scientists found that cancer cells in ER+ HER2- breast cancer can lose their luminal lineage identity under treatment pressure. This loss weakens the effect of ERα-targeting drugs, as the cells adopt a more stem-like state. The process is driven by changes in chromatin structure and gene expression, effectively bypassing the drug's blockade.

The study also reveals that the tumor's surroundings—including immune cells and stromal components—help push this transition. As treatment continues, cancer cells progressively shed their luminal markers, making them less responsive to therapy. Researchers noted that this shift is dynamic, accelerating as the disease faces more therapeutic pressure. Understanding these epigenetic and transcriptional changes could help reverse resistance. By mapping how cells reprogram themselves, scientists aim to develop strategies that restore drug sensitivity in resistant tumours.

The discovery of luminal lineage loss as a resistance mechanism offers a potential biomarker for patient stratification. Oncologists may now identify those less likely to respond to next-generation ERα antagonists. This insight also paves the way for new treatments designed to counteract the dedifferentiated state of resistant cancer cells.